Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

4D Molecular Therapeutics Inc (FDMT) USD0.0001

Sell:$30.38 Buy:$30.45 Change: $1.84 (5.71%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
Change: $1.84 (5.71%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
Change: $1.84 (5.71%)
Market closed |  Prices as at close on 28 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

4D Molecular Therapeutics, Inc. is a clinical-stage stage gene therapy company. The Company is focused on developing targeted therapies based on its adeno-associated viruses (AAV) vectors. It uses its Therapeutic Vector Evolution platform to customize its AAV vectors to target specific tissue types associated with the disease. The Company is focuses on three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector), and pulmonology (aerosol vector). The Company's product candidates include 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and 4D-710 for the treatment of cystic fibrosis lung disease.

Contact details

5858 Horton Street #455, Emeryville
United States
+1 (510) 5052680

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$949.45 million
Shares in issue:
26.99 million
United States
US dollar

Key personnel

  • John Milligan
    Executive Chairman of the Board
  • David Kirn
    Chief Executive Officer, Co-Founder, Director
  • August Moretti
    Chief Financial Officer
  • Robert Fishman
    Chief Medical Officer
  • Carolyne Zimmermann
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.